HCCS reviews applications related to the effects of chronic HIV infection and/or antiretroviral drug therapy on end organ diseases. Studies include basic science studies, animal models, and clinical studies.

Examples of end organ disease commonly seen includes cardiomyopathy, renal disease, liver disease, pulmonary dysfunction, neurocognitive and neurological disorders, metabolic complications, and diabetes. The study section also reviews applications involving clinical studies of HIV and aging, clinical management of symptoms and disease progression in children, pregnant women, adults and other defined cohorts.

The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.

Review Dates

Membership Panel

The membership panel is a list of chartered members only.


  • The mechanisms involved in CNS dysfunction, neuroimaging, neurological and neurocognitive studies.
  • The biological effects of drug abuse on the CNS and other organs in the context of HIV/AIDS.
  • Basic, clinical, and epidemiological studies of cardiovascular, pulmonary, hematologic, metabolic, digestive diseases and sleep comorbidities as a consequence of HIV infection and/or anti-retroviral treatment.
  • Studies of risk factors and/or biomarkers for HIV associated comorbidities.
  • Basic and clinical studies (with biological outcomes) of the effect of HIV on aging and interactions of the aging processes on HIV progression and comorbidities.
  • The clinical management of symptoms and disease associated with HIV infection in defined cohorts.
  • Clinical studies on the biological effects and efficacy of pre- and post-exposure prophylaxis in adults, including pregnant women, and children.
  • Clinical studies addressing inflammation and its contribution to organ disease in HIV infection and antiretroviral therapy.
  • Non-immunological clinical studies to characterize organ-based viral reservoirs and interventions to eliminate them.
  • Clinical studies on antiretroviral drug side effects and drug resistance including pharmacogenetics.